US-based drug maker Eli Lilly (NYSE:LLY) said on Thursday that is suing six more entities that are accused of selling counterfeit Mounjaro, Reuters reported on Thursday.
Medical spas and wellness centres are among the businesses facing legal action for allegedly selling products claimed to contain tirzepatide, the active ingredient in Lilly's diabetes drug Mounjaro.
Eli Lilly is the only company that has been approved by US Food and Drug Administration to sell the drug.
Lilly has also warned consumers against the use of counterfeit, fake, compounded, and any other unsafe or untested versions of what is claimed to be tirzepatide.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA